Ascendis Pharma A/S (NASDAQ:ASND) Coverage Initiated by Analysts at Morgan Stanley

Analysts at Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a research note issued on Thursday, Marketbeat reports. The firm set an "overweight" rating and a $250.00 price target on the biotechnology company's stock. Morgan Stanley's target price suggests a potential upside of 43.62% from the company's current price.

Other analysts also recently issued reports about the company. Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a report on Monday, June 9th. Wedbush increased their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Oppenheimer reiterated an "outperform" rating and set a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Finally, JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $220.67.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded up $0.97 on Thursday, reaching $174.07. The company had a trading volume of 157,816 shares, compared to its average volume of 501,661. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of -27.72 and a beta of 0.38. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The business has a 50 day moving average of $167.68 and a two-hundred day moving average of $152.36.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its position in shares of Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company's stock worth $1,602,474,000 after purchasing an additional 168,752 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after purchasing an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after purchasing an additional 39,309 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after purchasing an additional 193,688 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock worth $475,970,000 after purchasing an additional 328,278 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.